TEL-AVIV (July 24, 2017) – BioLight Life Sciences Ltd. (TASE: BOLT) , an emerging global ophthalmic company focused on the discovery, development and commercialization of ophthalmic products and product candidates, announced today successful results from its glaucoma insert VS101 Phase 1/2a clinical trial, which demonstrated its ability to lower intraocular pressure for a 12-week period, with a favorable safety profile.
Link to Newsroom